First-class academic journals have an important impact factor in the academic world, and the profit method depends on the support of a large number of journal subscriptions and major academic research funds.

There will be no impact factor for third-rate academic journals, nor will there be authoritative papers, and only rely on publishing papers with low academic value and making a living from the author's bad money.

Bioscience & Medical Technology has been doing this kind of rotten money for more than a decade.

However, existence is reasonable, although "Biological Science and Medical Technology" is very bad, it has also helped many students who need to evaluate their professional titles and get graduation certificates, so that they can achieve their small goals even if they are legally compliant but cannot write in-depth papers.

However, in the past few days, "Bioscience and Medical Technology" has changed its way of life.

Many universities, hospitals, and research institutions have purchased "Biological Sciences and Medical Technology", although they only ordered the issue of Origin Technology to publish papers, but this is also a very good start.

In the academic world, "Biological Sciences and Medical Technology" (hereinafter referred to as "Biomedicine") is known as the pearl of insight!

When heavy academic weeklies such as "Nature" and "Cell" in the West and "Biological Science" in China rejected papers on Origin Technology, "Biomedical Medicine" actually published it.

The editor-in-chief, Zhang Fengfeng, said how he discovered the paper on Origin Technology in the first place, how he was amazed, and decided to publish the paper.

The actual situation is that after Zhang Feng knew that the symbiotic protein treatment for respiratory diseases was popular, he knew that this paper was actually published by himself.

It's different from Zhang Feng's snort.

The headquarters of the journal "Biological Sciences" asked paper reviewers (many of them professionals from universities and research institutions) to re-examine why the paper was not published.

In the end, the experts unanimously came to a conclusion. If you reset the time, this paper still can't be reviewed, and the reason is still too advanced, like a rootless ping.

The experts discussed:

"There is no point in discussing this issue now, because the clinical trials of Bloomage and Origin Technology have been successful."

"I actually really want to go to Rongcheng to see those patients who have recovered after treatment, using symbiotic green leaf protein instead of lungs for breathing, which is unheard of and unthinkable."

That's what everyone said.

In fact, "Biological Science" is very regrettable in my heart, if the original thinking is a little more active, and the paper on the origin science and technology is published, it may establish the status of "Biological Science" as the first domestic academic journal.

An expert from Biological Sciences commented: "Since the authenticity of the paper has been clinically proven, this paper must have a historical place in the medical and biological circles, and it is a pity that we missed this opportunity." ”

Another expert said: "I have already contacted Bloomage Hospital, and next week I will participate in the whole process of symbiotic protein treatment for patients, and I also want to see how the links that we doubted when we reviewed the paper were realized." ”

The Xia Guo biomedical community is actively researching the paper and related experiments of symbiotic photosynthetic chlorophyllin of the origin technology to replace the lungs to deliver oxygen to the body, which has also attracted the attention of the media in Europe and the United States.

The New York Times, the BBC and many other Western media outlets stationed in Chengdu reported the news and called it an "impossible" experiment to verify it from the Western academic community.

Western medical and biological academia did not care about the experiments of origin technology, but under the questioning of the media, they have also been paying attention to the trends of Bloomage Hospital and technology.

If the clinical treatment of Origin Technology is really successful, it will definitely change the history of human biomedicine, and Western academics suspect that Origin Technology is academic fraud.

After all, symbiotic protein technology is unheard of, how did Xia Guoren, who is not very good at high-end medical technology, solve the problems in the history of human medicine!

This not only solves the problem, but also creates a new biomedical direction for the future of mankind!

How is this possible!

The world's leading country in medicine is the United States, which has never thought about the replacement of lung respiration with symbiotic proteins, how could an unknown Xia Guo company create a new biological discipline?

Why is the West the center of the world? Because the center of science and technology is in the West.

All the science and technology centers of mankind are the most important basic science and technology.

These basic technologies include mathematics, physics, chemistry, biomedicine, etc.

In terms of basic science, the West is in an absolute leading position, and the absolute leadership of basic science and technology means that the right to speak is ahead.

The monopoly of basic technology also means the monopoly of wealth.

Two very typical examples.

First, medical biology as an example, the world's top medical institutions are in the United States, and the best pharmaceutical companies are also in the United States.

Most of the anti-cancer drugs in Xia Guo are imported from the United States or Europe, and terminally ill patients with conditions also hope to go to the United States for treatment.

Those targeted drugs that are tens of thousands or more than 100,000 self-paid for a course of treatment at every turn are from Western pharmaceutical companies.

Because Xia Guo enterprises can't produce it, and the intellectual property rights are firmly in the hands of Westerners, they have a monopoly and are the only ones, and it is understandable to sell you at a high price (the pharmaceutical company that produces anti-cancer drugs in India only imitates the production process, and does not care about intellectual property rights, and does not develop and master the most fundamental core technology by itself).

Second, the core technology of chips based on new physical materials and computer-based science is also in the West.

Xia Guo will spend trillions of dollars on buying chips every year, and the cost of importing chips far exceeds the cost of importing oil.

The richest private companies in Xia include BTA, most of which are engaged in superficial Internet and software, and almost do not involve chips, because there is no technology and no talent.

Because Xia Guo's chip technology is subject to the technical barriers of the West, there is a difference of two to three generations between the most advanced technology of the West and the West, that is, more than ten or twenty years.

Based on these preconditions, when Origin Technology launches a certain subversive biomedical technology, the first reaction of the Western academic community is to be skeptical!

In an interview with the New York Times, several professors of biomedical sciences at Stanford University, the country's most prominent university, dismissed the research results of Origin Technology as impossible.

Middlel of Stanford University is an expert in respiratory medicine, and one of the world's most advanced targeted drugs for lung cancer, osimertinib, was developed by Middle's team in collaboration with AstraZeneca in the United Kingdom.

The price of osimertinib in China is about 16,000 per box, and patients need to take one box a month, which is unaffordable for most families

The monopoly of the life-saving drug allowed Middle's team to get handsomely paid by AstraZeneca.

Midl told reporters: "The treatment method of Origin Technology is absurd and unreasonable for Middel, it is impossible to realize, I don't comment on Xia Guo's academic environment, but I heard that Nature also rejected Xia Guo's paper, which says it all." ”